our Technologies

TechnoVax and its team of scientists have developed a new way to produce highly immunogenic, non-infectious monovalent and polyvalent virus-like particle (VLP) vaccines, using a cell-based manufacturing system.

Virus-like particles are structures that mimic the organization and conformation of native viruses but are non-infectious because they do not contain any viral genetic material, potentially yielding safer and cheaper vaccine candidates.

Our Unique and Novel VLPs (Virus-Like Particle) and Inhaled Powder platforms are used to develop and produce vaccines against infectious diseases such as:

  • Influenza (mono or multivalent, universal flu vaccines)

  • Respiratory Syncytial Virus (RSV vaccine),

  • Para-Influenza (PIV) and other diseases including Dengue, HIV and cancer.

Influenza virus

influenza.jpg

Influenza virus like particle (VLP)

vaccine.jpg

Resembles the virus but lacks nucleic acid and ability to replicate

Flu-VLP-300x259 copy.png

Examination of purified VLP by negatif staining EM.
Arrows indicate surface glycoproteins.